Day: March 14, 2024

Research & Development HighlightsPresented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activity Introduced the Switch-DARPin concept and platform at PEGS Europe. In January 2024, introduced the first multispecific Switch-DARPin program, targeting cKIT x CD16a x CD47, as a next-generation conditioning regimen for hematopoietic stem cell transplantation Presented positive preclinical data supporting the Radio-DARPin Therapy (RDT) platform and expansion of the RDT pipeline at multiple leading scientific conferences In January 2024, announced a strategic collaboration agreement with Orano Med to co-develop 212Pb-based RDTs for multiple oncology...

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) — Tekumo Inc. (or the “Company”) announces its results for Q4, 2023. Revenue for the fourth quarter increased 281% year-over-year to $1.37 million. Revenue growth for Q4, 2023 increased 60% over Q3 2023.FINANCIAL UPDATEIn the second half of 2023, Tekumo reported revenue of $2.23 million, achieving an annualized revenue run rate above $5 million in Q4. Significantly, the Company reported positive net ordinary income in Q4. Phillip Dignan, President & CFO states, “The first quarter of 2024 continues to show impressive year-over-year growth. We have integrated a managed services division that has signed multiple contracts scheduled to begin in early Q2.” Mr. Dignan continues, “We have also reduced our convertible debt balance by over $400K, continuing to improve our...

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023...

Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients Alive and Progression Free Past 12 MonthsPresented Positive Results from a Phase 1 Study in Newly Diagnosed Glioblastoma (GBM) Demonstrating All Patients Treated with INB-200 Exceeded Progression-Free Survival (PFS) of Seven Months at the Society for Neuro-Oncology (SNO) 28th Annual MeetingAppointed Dr. Corinne Epperly, M.D., M.P.H. to Board of DirectorsClosed Private Placement in December 2023 with Initial Gross Proceeds of $14.4 Million to Provide Cash Runway into 1Q 2025NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative...

FRAMINGHAM, Mass., March 14, 2024 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it has been named one of the Boston Business Journal’s Middle Market Leaders for 2024, a ranking of the 50 highest growth companies in Massachusetts. This marks the second year in a row that Definitive Healthcare has won this award. The Boston Business Journal selects the Middle Market Leaders using a weighted index score based on revenue growth from 2020 to 2022. For a company to qualify, it must report annual revenue between $25 million and $1 billion from 2020 to 2022. From 2020 to 2022, Definitive Healthcare’s total revenue grew from $118.3 million to $222.7 million. At the end of the financial year 2022, the company exited with a 34% year-over-year increase. “We’re...

Map of regionMap of regionTORONTO, March 14, 2024 (GLOBE NEWSWIRE) — Sintana Energy Inc. (TSX-V: SEI, OTCQB: SEUSF) (“Sintana” or the “Company”) is pleased to provide the following update regarding the ongoing exploration campaign on blocks 2813A and 2814B located in the heart of Namibia’s Orange Basin, emerging as the one of the world’s most prospective oil and gas regions. The blocks are governed by Petroleum Exploration License 83 (“PEL 83”) which is operated by a subsidiary of Galp Energia (“Galp”) of Portugal. Sintana maintains an indirect 49% interest in Custos Energy (Pty) Ltd. (“Custos”), a 10% working interest owner in PEL 83. NAMCOR, the National Petroleum Company of Namibia, also maintains a 10% working interest.We refer to press releases from Galp (available at galp.com) and Custos (available at newsdirect.com)...

SINGAPORE, March 14, 2024 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, and FatBrain AI (“FatBrain AI”) an AI SaaS and Solutions company (OTCMKTS:LZGI) today announced completion of their merger to form an AI-powered Education and Acceleration group to power Sovereign AI ecosystems of tomorrow for entrepreneurs, enterprises, governments and students through AI education and enablement. Following NYSE approval, Genius Group completed the merger, acquiring FatBrain AI in an all-stock transaction. Under the terms of the agreement, Genius Group has acquired the AI software assets, customer relationships and specific operations of FatBrain AI, with an anticipated increase of approximately 150% in the Company’s 2023 pro forma revenue...

SCV Safety Summit1. The Live Broadcast 2. The full video gets archived on our YouTube channel indefinitely3. All of the content we’ll cut from the final production. Each guest will get 5-10+ short clips from their segment and Q&AAUSTIN, Texas, March 14, 2024 (GLOBE NEWSWIRE) — Austin, Texas-based SmallCapVoice.com Inc. (“SCV”) announced an upcoming webinar and live Q&A session with several rising stars in key support roles to first responders, airline safety, enhanced security and public safety. SmallCapVoice.com, Inc. is an investor relations and communications firm focused on socially responsible investments and companies. Stuart Smith CEO of SmallCapVoice.com, Inc., commented, “I am excited to shine a spotlight once again on these companies that have built their business models around key revenue drivers...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English translation on Fagron’s website. Further informationKaren BergGlobal Investor Relations ManagerTel. +31 6 53 44 91 99karen.berg@fagron.com About FagronFagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world....

              Press Release     Paris – March 14th, 2024 – EUROAPI today announces that its Italian subsidiary, EUROAPI Italy S.R.L., is suspending the production of all APIs1 in Brindisi. Following an internal audit, quality control deficiencies due to potential local misconduct have been identified and are being further investigated. Production will remain suspended until further notice. The relevant health authorities have been informed. The company has initiated a forensic audit and will inform its customers. The Brindisi site produces 11 APIs and intermediates, mostly anti-infectives (including spiramycin, rifaximin, rifampicin and teicoplanin). In 2023, sales related to the Brindisi site amounted to 63 million euros, of which 43% related to Sanofi. The value of Brindisi non-current assets has been fully impaired in 2023 Consolidated...